ZA200400074B - A G-protein coupled receptor and uses thereof - Google Patents

Info

Publication number

ZA200400074B

ZA200400074B ZA200400074A ZA200400074A ZA200400074B ZA 200400074 B ZA200400074 B ZA 200400074B ZA 200400074 A ZA200400074 A ZA 200400074A ZA 200400074 A ZA200400074 A ZA 200400074A ZA 200400074 B ZA200400074 B ZA 200400074B

Authority

ZA

South Africa

Prior art keywords

hcar

protein

gene

nucleic acid

cells

Prior art date

2001-06-07

Links

• Espacenet
• Global Dossier
• Discuss

• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 title description 41
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 title description 41
• 101000858031 Homo sapiens Coxsackievirus and adenovirus receptor Proteins 0.000 claims description 694
• 102100025278 Coxsackievirus and adenovirus receptor Human genes 0.000 claims description 584
• 108090000623 proteins and genes Proteins 0.000 claims description 219
• 150000007523 nucleic acids Chemical class 0.000 claims description 164
• 238000000034 method Methods 0.000 claims description 163
• 102000039446 nucleic acids Human genes 0.000 claims description 157
• 108020004707 nucleic acids Proteins 0.000 claims description 157
• 230000014509 gene expression Effects 0.000 claims description 139
• 102000004169 proteins and genes Human genes 0.000 claims description 121
• 241000282414 Homo sapiens Species 0.000 claims description 105
• 239000012634 fragment Substances 0.000 claims description 93
• 150000001875 compounds Chemical class 0.000 claims description 80
• 125000003729 nucleotide group Chemical group 0.000 claims description 71
• 239000002773 nucleotide Substances 0.000 claims description 69
• 239000013598 vector Substances 0.000 claims description 67
• 230000000694 effects Effects 0.000 claims description 63
• 241001465754 Metazoa Species 0.000 claims description 60
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 57
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 56
• 230000000692 anti-sense effect Effects 0.000 claims description 47
• 239000000203 mixture Substances 0.000 claims description 38
• 230000001105 regulatory effect Effects 0.000 claims description 33
• 230000027455 binding Effects 0.000 claims description 26
• 230000000295 complement effect Effects 0.000 claims description 26
• 108091026890 Coding region Proteins 0.000 claims description 23
• 238000003556 assay Methods 0.000 claims description 23
• 230000009261 transgenic effect Effects 0.000 claims description 22
• 108700019146 Transgenes Proteins 0.000 claims description 21
• 238000004519 manufacturing process Methods 0.000 claims description 21
• 238000011282 treatment Methods 0.000 claims description 21
• 238000012360 testing method Methods 0.000 claims description 20
• 101150011183 hcaR gene Proteins 0.000 claims description 19
• 239000000126 substance Substances 0.000 claims description 18
• 238000002360 preparation method Methods 0.000 claims description 17
• 230000002401 inhibitory effect Effects 0.000 claims description 16
• 230000004913 activation Effects 0.000 claims description 13
• 238000001514 detection method Methods 0.000 claims description 13
• 108700028369 Alleles Proteins 0.000 claims description 9
• 108091092724 Noncoding DNA Proteins 0.000 claims description 7
• 230000005764 inhibitory process Effects 0.000 claims description 7
• 239000002253 acid Substances 0.000 claims description 5
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
• 230000001939 inductive effect Effects 0.000 claims description 4
• 230000006698 induction Effects 0.000 claims description 3
• 238000000159 protein binding assay Methods 0.000 claims description 2
• 108700026220 vif Genes Proteins 0.000 claims description 2
• 229920002477 rna polymer Polymers 0.000 claims 5
• 101150036876 cre gene Proteins 0.000 claims 4
• 210000004027 cell Anatomy 0.000 description 307
• 235000018102 proteins Nutrition 0.000 description 99
• 108020004414 DNA Proteins 0.000 description 98
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 71
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 54
• 235000001014 amino acid Nutrition 0.000 description 48
• 239000000523 sample Substances 0.000 description 47
• 108020004999 messenger RNA Proteins 0.000 description 44
• 239000003814 drug Substances 0.000 description 42
• 102000004196 processed proteins & peptides Human genes 0.000 description 42
• 230000004952 protein activity Effects 0.000 description 41
• 239000003795 chemical substances by application Substances 0.000 description 39
• 239000013604 expression vector Substances 0.000 description 38
• 229940079593 drug Drugs 0.000 description 37
• 210000001519 tissue Anatomy 0.000 description 36
• 229940024606 amino acid Drugs 0.000 description 31
• 150000001413 amino acids Chemical class 0.000 description 31
• 210000000349 chromosome Anatomy 0.000 description 31
• 239000002299 complementary DNA Substances 0.000 description 31
• 208000035475 disorder Diseases 0.000 description 31
• 102000037865 fusion proteins Human genes 0.000 description 29
• 108020001507 fusion proteins Proteins 0.000 description 29
• 229920001184 polypeptide Polymers 0.000 description 29
• 239000013615 primer Substances 0.000 description 29
• 230000035772 mutation Effects 0.000 description 28
• 239000013612 plasmid Substances 0.000 description 28
• 102000005962 receptors Human genes 0.000 description 28
• 108020003175 receptors Proteins 0.000 description 28
• 238000003752 polymerase chain reaction Methods 0.000 description 26
• 241000699666 Mus <mouse, genus> Species 0.000 description 25
• 108091028043 Nucleic acid sequence Proteins 0.000 description 25
• 238000009396 hybridization Methods 0.000 description 25
• 102000040430 polynucleotide Human genes 0.000 description 25
• 108091033319 polynucleotide Proteins 0.000 description 25
• 239000002157 polynucleotide Substances 0.000 description 25
• 230000008685 targeting Effects 0.000 description 24
• 230000001225 therapeutic effect Effects 0.000 description 24
• 201000010099 disease Diseases 0.000 description 23
• 238000004458 analytical method Methods 0.000 description 22
• 239000003446 ligand Substances 0.000 description 22
• 241000699670 Mus sp. Species 0.000 description 21
• 230000004927 fusion Effects 0.000 description 21
• 239000000047 product Substances 0.000 description 20
• 102000004190 Enzymes Human genes 0.000 description 19
• 108090000790 Enzymes Proteins 0.000 description 19
• 241001529936 Murinae Species 0.000 description 19
• 230000001594 aberrant effect Effects 0.000 description 19
• 229940088598 enzyme Drugs 0.000 description 19
• IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 18
• IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 18
• 230000002159 abnormal effect Effects 0.000 description 18
• 229940095074 cyclic amp Drugs 0.000 description 18
• 210000004556 brain Anatomy 0.000 description 17
• 108091006027 G proteins Proteins 0.000 description 16
• 102000030782 GTP binding Human genes 0.000 description 16
• 108091000058 GTP-Binding Proteins 0.000 description 16
• -1 inositol phosphates Chemical class 0.000 description 16
• 238000001890 transfection Methods 0.000 description 16
• 239000003153 chemical reaction reagent Substances 0.000 description 15
• 238000002744 homologous recombination Methods 0.000 description 15
• 230000006801 homologous recombination Effects 0.000 description 15
• 238000006467 substitution reaction Methods 0.000 description 15
• 241000588724 Escherichia coli Species 0.000 description 14
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 14
• 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 14
• 239000012472 biological sample Substances 0.000 description 14
• 230000000875 corresponding effect Effects 0.000 description 14
• 230000006870 function Effects 0.000 description 14
• 239000003550 marker Substances 0.000 description 14
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
• 230000015572 biosynthetic process Effects 0.000 description 13
• 210000002950 fibroblast Anatomy 0.000 description 13
• 238000000338 in vitro Methods 0.000 description 13
• 230000003993 interaction Effects 0.000 description 13
• 230000001404 mediated effect Effects 0.000 description 13
• 238000012216 screening Methods 0.000 description 13
• 238000007423 screening assay Methods 0.000 description 13
• 238000013518 transcription Methods 0.000 description 13
• 230000035897 transcription Effects 0.000 description 13
• 230000014616 translation Effects 0.000 description 13
• 238000011144 upstream manufacturing Methods 0.000 description 13
• 241000124008 Mammalia Species 0.000 description 12
• 239000000427 antigen Substances 0.000 description 12
• 102000036639 antigens Human genes 0.000 description 12
• 230000001580 bacterial effect Effects 0.000 description 12
• 239000002609 medium Substances 0.000 description 12
• 102000053642 Catalytic RNA Human genes 0.000 description 11
• 108090000994 Catalytic RNA Proteins 0.000 description 11
• 125000000539 amino acid group Chemical group 0.000 description 11
• 108091007433 antigens Proteins 0.000 description 11
• 238000001415 gene therapy Methods 0.000 description 11
• 238000003259 recombinant expression Methods 0.000 description 11
• 108091092562 ribozyme Proteins 0.000 description 11
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 10
• 102000005720 Glutathione transferase Human genes 0.000 description 10
• 108010070675 Glutathione transferase Proteins 0.000 description 10
• 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 10
• 108091034117 Oligonucleotide Proteins 0.000 description 10
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 10
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 10
• 238000012217 deletion Methods 0.000 description 10
• 230000037430 deletion Effects 0.000 description 10
• 210000004408 hybridoma Anatomy 0.000 description 10
• 230000002163 immunogen Effects 0.000 description 10
• 238000003780 insertion Methods 0.000 description 10
• 230000037431 insertion Effects 0.000 description 10
• 102000054765 polymorphisms of proteins Human genes 0.000 description 10
• 108091008146 restriction endonucleases Proteins 0.000 description 10
• 238000010561 standard procedure Methods 0.000 description 10
• 238000013519 translation Methods 0.000 description 10
• 102000030621 adenylate cyclase Human genes 0.000 description 9
• 108060000200 adenylate cyclase Proteins 0.000 description 9
• 238000005516 engineering process Methods 0.000 description 9
• 210000003917 human chromosome Anatomy 0.000 description 9
• 238000001727 in vivo Methods 0.000 description 9
• 230000001965 increasing effect Effects 0.000 description 9
• 230000002974 pharmacogenomic effect Effects 0.000 description 9
• 210000002826 placenta Anatomy 0.000 description 9
• 230000004044 response Effects 0.000 description 9
• 150000003384 small molecules Chemical class 0.000 description 9
• 241000894007 species Species 0.000 description 9
• 238000003786 synthesis reaction Methods 0.000 description 9
• 230000007306 turnover Effects 0.000 description 9
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
• 206010035226 Plasma cell myeloma Diseases 0.000 description 8
• 230000003321 amplification Effects 0.000 description 8
• 239000000872 buffer Substances 0.000 description 8
• 230000001413 cellular effect Effects 0.000 description 8
• 238000006243 chemical reaction Methods 0.000 description 8
• 230000002759 chromosomal effect Effects 0.000 description 8
• 238000010276 construction Methods 0.000 description 8
• 239000000499 gel Substances 0.000 description 8
• 238000013507 mapping Methods 0.000 description 8
• 239000000463 material Substances 0.000 description 8
• 201000000050 myeloid neoplasm Diseases 0.000 description 8
• 238000003199 nucleic acid amplification method Methods 0.000 description 8
• 150000003905 phosphatidylinositols Chemical class 0.000 description 8
• 230000019491 signal transduction Effects 0.000 description 8
• 108020005544 Antisense RNA Proteins 0.000 description 7
• 108091029865 Exogenous DNA Proteins 0.000 description 7
• 230000009471 action Effects 0.000 description 7
• 230000008859 change Effects 0.000 description 7
• 238000010367 cloning Methods 0.000 description 7
• 230000003053 immunization Effects 0.000 description 7
• 230000004060 metabolic process Effects 0.000 description 7
• 230000037361 pathway Effects 0.000 description 7
• 239000008194 pharmaceutical composition Substances 0.000 description 7
• WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 7
• 230000003612 virological effect Effects 0.000 description 7
• 229920000936 Agarose Polymers 0.000 description 6
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
• OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 6
• 108060003951 Immunoglobulin Proteins 0.000 description 6
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 6
• 241001045988 Neogene Species 0.000 description 6
• 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 6
• 108091023040 Transcription factor Proteins 0.000 description 6
• 102000040945 Transcription factor Human genes 0.000 description 6
• 239000000556 agonist Substances 0.000 description 6
• 239000003242 anti bacterial agent Substances 0.000 description 6
• 239000003184 complementary RNA Substances 0.000 description 6
• 230000007423 decrease Effects 0.000 description 6
• 238000011161 development Methods 0.000 description 6
• 230000018109 developmental process Effects 0.000 description 6
• 238000007878 drug screening assay Methods 0.000 description 6
• 239000003623 enhancer Substances 0.000 description 6
• 230000009368 gene silencing by RNA Effects 0.000 description 6
• 230000002068 genetic effect Effects 0.000 description 6
• 229930195712 glutamate Natural products 0.000 description 6
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
• 102000018358 immunoglobulin Human genes 0.000 description 6
• 210000004962 mammalian cell Anatomy 0.000 description 6
• 239000012528 membrane Substances 0.000 description 6
• 230000004048 modification Effects 0.000 description 6
• 238000012986 modification Methods 0.000 description 6
• 238000010369 molecular cloning Methods 0.000 description 6
• 230000036961 partial effect Effects 0.000 description 6
• 238000012163 sequencing technique Methods 0.000 description 6
• 239000011780 sodium chloride Substances 0.000 description 6
• 239000000243 solution Substances 0.000 description 6
• LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 5
• 102000053602 DNA Human genes 0.000 description 5
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
• 241000282412 Homo Species 0.000 description 5
• 229930193140 Neomycin Natural products 0.000 description 5
• 108700026244 Open Reading Frames Proteins 0.000 description 5
• 108010076504 Protein Sorting Signals Proteins 0.000 description 5
• 108020004511 Recombinant DNA Proteins 0.000 description 5
• 108010091086 Recombinases Proteins 0.000 description 5
• 102000018120 Recombinases Human genes 0.000 description 5
• 238000002105 Southern blotting Methods 0.000 description 5
• 108091081024 Start codon Proteins 0.000 description 5
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 5
• 230000004075 alteration Effects 0.000 description 5
• 238000013459 approach Methods 0.000 description 5
• 230000004888 barrier function Effects 0.000 description 5
• 210000002459 blastocyst Anatomy 0.000 description 5
• 210000003169 central nervous system Anatomy 0.000 description 5
• 210000003710 cerebral cortex Anatomy 0.000 description 5
• 238000003776 cleavage reaction Methods 0.000 description 5
• 230000001419 dependent effect Effects 0.000 description 5
• 206010014599 encephalitis Diseases 0.000 description 5
• ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 5
• 229960005542 ethidium bromide Drugs 0.000 description 5
• 238000010363 gene targeting Methods 0.000 description 5
• 210000004754 hybrid cell Anatomy 0.000 description 5
• 230000003834 intracellular effect Effects 0.000 description 5
• 238000002372 labelling Methods 0.000 description 5
• 239000006166 lysate Substances 0.000 description 5
• 239000011159 matrix material Substances 0.000 description 5
• 101150091879 neo gene Proteins 0.000 description 5
• 229960004927 neomycin Drugs 0.000 description 5
• 208000015122 neurodegenerative disease Diseases 0.000 description 5
• 210000000287 oocyte Anatomy 0.000 description 5
• 230000008569 process Effects 0.000 description 5
• 238000000746 purification Methods 0.000 description 5
• 230000007017 scission Effects 0.000 description 5
• 230000011664 signaling Effects 0.000 description 5
• 238000002741 site-directed mutagenesis Methods 0.000 description 5
• 230000000638 stimulation Effects 0.000 description 5
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
• 108091033380 Coding strand Proteins 0.000 description 4
• 108020004705 Codon Proteins 0.000 description 4
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
• 238000002965 ELISA Methods 0.000 description 4
• 108010010803 Gelatin Proteins 0.000 description 4
• 241000238631 Hexapoda Species 0.000 description 4
• 208000012902 Nervous system disease Diseases 0.000 description 4
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
• 238000010240 RT-PCR analysis Methods 0.000 description 4
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
• 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
• 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 description 4
• 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 4
• 230000001154 acute effect Effects 0.000 description 4
• 239000011543 agarose gel Substances 0.000 description 4
• 229960000723 ampicillin Drugs 0.000 description 4
• 239000005557 antagonist Substances 0.000 description 4
• 230000000890 antigenic effect Effects 0.000 description 4
• 230000004071 biological effect Effects 0.000 description 4
• 229960002685 biotin Drugs 0.000 description 4
• 235000020958 biotin Nutrition 0.000 description 4
• 239000011616 biotin Substances 0.000 description 4
• 210000001638 cerebellum Anatomy 0.000 description 4
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
• RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 4
• 238000013461 design Methods 0.000 description 4
• 239000006185 dispersion Substances 0.000 description 4
• 239000003937 drug carrier Substances 0.000 description 4
• 238000004520 electroporation Methods 0.000 description 4
• 210000001671 embryonic stem cell Anatomy 0.000 description 4
• 230000002255 enzymatic effect Effects 0.000 description 4
• 210000003527 eukaryotic cell Anatomy 0.000 description 4
• 239000012530 fluid Substances 0.000 description 4
• 238000001502 gel electrophoresis Methods 0.000 description 4
• 239000008273 gelatin Substances 0.000 description 4
• 229920000159 gelatin Polymers 0.000 description 4
• 235000019322 gelatine Nutrition 0.000 description 4
• 235000011852 gelatine desserts Nutrition 0.000 description 4
• 210000004602 germ cell Anatomy 0.000 description 4
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
• 239000001963 growth medium Substances 0.000 description 4
• 210000005260 human cell Anatomy 0.000 description 4
• FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
• 238000001114 immunoprecipitation Methods 0.000 description 4
• 238000007901 in situ hybridization Methods 0.000 description 4
• 239000004615 ingredient Substances 0.000 description 4
• 238000002347 injection Methods 0.000 description 4
• 239000007924 injection Substances 0.000 description 4
• 238000002955 isolation Methods 0.000 description 4
• 210000004698 lymphocyte Anatomy 0.000 description 4
• 201000011475 meningoencephalitis Diseases 0.000 description 4
• 238000012544 monitoring process Methods 0.000 description 4
• 238000002703 mutagenesis Methods 0.000 description 4
• 231100000350 mutagenesis Toxicity 0.000 description 4
• 229920001223 polyethylene glycol Polymers 0.000 description 4
• 210000001236 prokaryotic cell Anatomy 0.000 description 4
• 230000002829 reductive effect Effects 0.000 description 4
• 230000010076 replication Effects 0.000 description 4
• 230000002441 reversible effect Effects 0.000 description 4
• 230000028327 secretion Effects 0.000 description 4
• 239000002904 solvent Substances 0.000 description 4
• 230000004936 stimulating effect Effects 0.000 description 4
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
• 210000003523 substantia nigra Anatomy 0.000 description 4
• 239000004475 Arginine Substances 0.000 description 3
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
• 206010003571 Astrocytoma Diseases 0.000 description 3
• 241000894006 Bacteria Species 0.000 description 3
• 101150074155 DHFR gene Proteins 0.000 description 3
• 108020003215 DNA Probes Proteins 0.000 description 3
• 239000003155 DNA primer Substances 0.000 description 3
• 239000003298 DNA probe Substances 0.000 description 3
• SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 3
• 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 3
• 108010024636 Glutathione Proteins 0.000 description 3
• 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 3
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
• 239000004472 Lysine Substances 0.000 description 3
• 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 3
• 201000009906 Meningitis Diseases 0.000 description 3
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
• 208000001089 Multiple system atrophy Diseases 0.000 description 3
• 206010028980 Neoplasm Diseases 0.000 description 3
• 208000009905 Neurofibromatoses Diseases 0.000 description 3
• 238000000636 Northern blotting Methods 0.000 description 3
• 238000012408 PCR amplification Methods 0.000 description 3
• 229910019142 PO4 Inorganic materials 0.000 description 3
• 208000018737 Parkinson disease Diseases 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• 102100022831 Somatoliberin Human genes 0.000 description 3
• 101710142969 Somatoliberin Proteins 0.000 description 3
• 108010090804 Streptavidin Proteins 0.000 description 3
• 108091036066 Three prime untranslated region Proteins 0.000 description 3
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
• 239000004473 Threonine Substances 0.000 description 3
• 239000007983 Tris buffer Substances 0.000 description 3
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
• 239000002671 adjuvant Substances 0.000 description 3
• 230000000735 allogeneic effect Effects 0.000 description 3
• 229940088710 antibiotic agent Drugs 0.000 description 3
• 239000000074 antisense oligonucleotide Substances 0.000 description 3
• 238000012230 antisense oligonucleotides Methods 0.000 description 3
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
• 229960001230 asparagine Drugs 0.000 description 3
• 235000009582 asparagine Nutrition 0.000 description 3
• 229940009098 aspartate Drugs 0.000 description 3
• 239000011324 bead Substances 0.000 description 3
• 230000033228 biological regulation Effects 0.000 description 3
• 230000005540 biological transmission Effects 0.000 description 3
• 210000004369 blood Anatomy 0.000 description 3
• 239000008280 blood Substances 0.000 description 3
• 210000005013 brain tissue Anatomy 0.000 description 3
• 239000011575 calcium Substances 0.000 description 3
• 239000001506 calcium phosphate Substances 0.000 description 3
• 229910000389 calcium phosphate Inorganic materials 0.000 description 3
• 235000011010 calcium phosphates Nutrition 0.000 description 3
• 125000002091 cationic group Chemical group 0.000 description 3
• 238000012512 characterization method Methods 0.000 description 3
• 238000003200 chromosome mapping Methods 0.000 description 3
• OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 3
• 238000012258 culturing Methods 0.000 description 3
• 230000001186 cumulative effect Effects 0.000 description 3
• 230000002950 deficient Effects 0.000 description 3
• 230000029087 digestion Effects 0.000 description 3
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
• 239000002612 dispersion medium Substances 0.000 description 3
• 230000002964 excitative effect Effects 0.000 description 3
• 238000009472 formulation Methods 0.000 description 3
• 238000001476 gene delivery Methods 0.000 description 3
• 229960003180 glutathione Drugs 0.000 description 3
• 210000001320 hippocampus Anatomy 0.000 description 3
• 208000015181 infectious disease Diseases 0.000 description 3
• 239000003112 inhibitor Substances 0.000 description 3
• 230000010354 integration Effects 0.000 description 3
• 229960000310 isoleucine Drugs 0.000 description 3
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
• 210000001161 mammalian embryo Anatomy 0.000 description 3
• 229930182817 methionine Natural products 0.000 description 3
• 229960000485 methotrexate Drugs 0.000 description 3
• 238000000520 microinjection Methods 0.000 description 3
• 201000004931 neurofibromatosis Diseases 0.000 description 3
• 210000002569 neuron Anatomy 0.000 description 3
• 210000000496 pancreas Anatomy 0.000 description 3
• 238000002823 phage display Methods 0.000 description 3
• 235000021317 phosphate Nutrition 0.000 description 3
• 239000002953 phosphate buffered saline Substances 0.000 description 3
• 230000026731 phosphorylation Effects 0.000 description 3
• 238000006366 phosphorylation reaction Methods 0.000 description 3
• 230000008488 polyadenylation Effects 0.000 description 3
• 230000032361 posttranscriptional gene silencing Effects 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 230000000750 progressive effect Effects 0.000 description 3
• 238000011321 prophylaxis Methods 0.000 description 3
• 235000021251 pulses Nutrition 0.000 description 3
• 210000002637 putamen Anatomy 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 3
• 239000004017 serum-free culture medium Substances 0.000 description 3
• 239000011734 sodium Substances 0.000 description 3
• 210000001082 somatic cell Anatomy 0.000 description 3
• 210000004988 splenocyte Anatomy 0.000 description 3
• 210000000130 stem cell Anatomy 0.000 description 3
• 239000006228 supernatant Substances 0.000 description 3
• 239000003826 tablet Substances 0.000 description 3
• 238000002560 therapeutic procedure Methods 0.000 description 3
• 229960004072 thrombin Drugs 0.000 description 3
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
• 241000701447 unidentified baculovirus Species 0.000 description 3
• 239000004474 valine Substances 0.000 description 3
• NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
• YSAJFXWTVFGPAX-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetic acid Chemical compound OC(=O)COC1=CNC(=O)NC1=O YSAJFXWTVFGPAX-UHFFFAOYSA-N 0.000 description 2
• FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 2
• OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 2
• ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 2
• RJOXFJDOUQJOMQ-UHFFFAOYSA-N 6-sulfanylidene-3,7-dihydropurin-2-one Chemical compound S=C1NC(=O)NC2=C1NC=N2 RJOXFJDOUQJOMQ-UHFFFAOYSA-N 0.000 description 2
• 229920001817 Agar Polymers 0.000 description 2
• 108010011667 Ala-Phe-Ala Proteins 0.000 description 2
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
• 208000019901 Anxiety disease Diseases 0.000 description 2
• HQIZDMIGUJOSNI-IUCAKERBSA-N Arg-Gly-Arg Chemical compound N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O HQIZDMIGUJOSNI-IUCAKERBSA-N 0.000 description 2
• NMRHDSAOIURTNT-RWMBFGLXSA-N Arg-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N NMRHDSAOIURTNT-RWMBFGLXSA-N 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
• 201000006474 Brain Ischemia Diseases 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
• 241000282472 Canis lupus familiaris Species 0.000 description 2
• 241000283707 Capra Species 0.000 description 2
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
• 102000000844 Cell Surface Receptors Human genes 0.000 description 2
• 108010001857 Cell Surface Receptors Proteins 0.000 description 2
• 206010008120 Cerebral ischaemia Diseases 0.000 description 2
• 241000699802 Cricetulus griseus Species 0.000 description 2
• 102100029363 Cytochrome P450 2C19 Human genes 0.000 description 2
• 230000004568 DNA-binding Effects 0.000 description 2
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
• 208000016192 Demyelinating disease Diseases 0.000 description 2
• 102100034581 Dihydroorotase Human genes 0.000 description 2
• 101000658547 Escherichia coli (strain K12) Type I restriction enzyme EcoKI endonuclease subunit Proteins 0.000 description 2
• 101000658543 Escherichia coli Type I restriction enzyme EcoAI endonuclease subunit Proteins 0.000 description 2
• 101000658546 Escherichia coli Type I restriction enzyme EcoEI endonuclease subunit Proteins 0.000 description 2
• 101000658530 Escherichia coli Type I restriction enzyme EcoR124II endonuclease subunit Proteins 0.000 description 2
• 101000658540 Escherichia coli Type I restriction enzyme EcoprrI endonuclease subunit Proteins 0.000 description 2
• 208000025499 G6PD deficiency Diseases 0.000 description 2
• 241000287828 Gallus gallus Species 0.000 description 2
• 206010071602 Genetic polymorphism Diseases 0.000 description 2
• VPKBCVUDBNINAH-GARJFASQSA-N Glu-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)O)N)C(=O)O VPKBCVUDBNINAH-GARJFASQSA-N 0.000 description 2
• 206010018444 Glucose-6-phosphate dehydrogenase deficiency Diseases 0.000 description 2
• 239000004471 Glycine Substances 0.000 description 2
• HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 2
• 101000658545 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Type I restriction enyme HindI endonuclease subunit Proteins 0.000 description 2
• 208000032843 Hemorrhage Diseases 0.000 description 2
• 208000007514 Herpes zoster Diseases 0.000 description 2
• 108091027305 Heteroduplex Proteins 0.000 description 2
• SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
• NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
• 206010062767 Hypophysitis Diseases 0.000 description 2
• UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
• 206010061216 Infarction Diseases 0.000 description 2
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
• UGTHTQWIQKEDEH-BQBZGAKWSA-N L-alanyl-L-prolylglycine zwitterion Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UGTHTQWIQKEDEH-BQBZGAKWSA-N 0.000 description 2
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
• 108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
• 108060001084 Luciferase Proteins 0.000 description 2
• 239000005089 Luciferase Substances 0.000 description 2
• 208000016604 Lyme disease Diseases 0.000 description 2
• MVBZBRKNZVJEKK-DTWKUNHWSA-N Met-Gly-Pro Chemical compound CSCC[C@@H](C(=O)NCC(=O)N1CCC[C@@H]1C(=O)O)N MVBZBRKNZVJEKK-DTWKUNHWSA-N 0.000 description 2
• 101000658548 Methanocaldococcus jannaschii (strain ATCC 43067 / DSM 2661 / JAL-1 / JCM 10045 / NBRC 100440) Putative type I restriction enzyme MjaIXP endonuclease subunit Proteins 0.000 description 2
• 101000658542 Methanocaldococcus jannaschii (strain ATCC 43067 / DSM 2661 / JAL-1 / JCM 10045 / NBRC 100440) Putative type I restriction enzyme MjaVIIIP endonuclease subunit Proteins 0.000 description 2
• 101000658529 Methanocaldococcus jannaschii (strain ATCC 43067 / DSM 2661 / JAL-1 / JCM 10045 / NBRC 100440) Putative type I restriction enzyme MjaVIIP endonuclease subunit Proteins 0.000 description 2
• 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 description 2
• 208000025966 Neurological disease Diseases 0.000 description 2
• 229930182555 Penicillin Natural products 0.000 description 2
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
• 102000007079 Peptide Fragments Human genes 0.000 description 2
• 108010033276 Peptide Fragments Proteins 0.000 description 2
• 108010001441 Phosphopeptides Proteins 0.000 description 2
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
• 102000004257 Potassium Channel Human genes 0.000 description 2
• 208000024777 Prion disease Diseases 0.000 description 2
• LGSANCBHSMDFDY-GARJFASQSA-N Pro-Glu-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCC(=O)O)C(=O)N2CCC[C@@H]2C(=O)O LGSANCBHSMDFDY-GARJFASQSA-N 0.000 description 2
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
• 108700008625 Reporter Genes Proteins 0.000 description 2
• 108090000820 Rhodopsin Proteins 0.000 description 2
• 102000006382 Ribonucleases Human genes 0.000 description 2
• 108010083644 Ribonucleases Proteins 0.000 description 2
• 108010086019 Secretin Proteins 0.000 description 2
• 102100037505 Secretin Human genes 0.000 description 2
• 238000012300 Sequence Analysis Methods 0.000 description 2
• 101001042773 Staphylococcus aureus (strain COL) Type I restriction enzyme SauCOLORF180P endonuclease subunit Proteins 0.000 description 2
• 101000838760 Staphylococcus aureus (strain MRSA252) Type I restriction enzyme SauMRSORF196P endonuclease subunit Proteins 0.000 description 2
• 101000838761 Staphylococcus aureus (strain MSSA476) Type I restriction enzyme SauMSSORF170P endonuclease subunit Proteins 0.000 description 2
• 101000838758 Staphylococcus aureus (strain MW2) Type I restriction enzyme SauMW2ORF169P endonuclease subunit Proteins 0.000 description 2
• 101001042566 Staphylococcus aureus (strain Mu50 / ATCC 700699) Type I restriction enzyme SauMu50ORF195P endonuclease subunit Proteins 0.000 description 2
• 101000838763 Staphylococcus aureus (strain N315) Type I restriction enzyme SauN315I endonuclease subunit Proteins 0.000 description 2
• 101000838759 Staphylococcus epidermidis (strain ATCC 35984 / RP62A) Type I restriction enzyme SepRPIP endonuclease subunit Proteins 0.000 description 2
• 101000838756 Staphylococcus saprophyticus subsp. saprophyticus (strain ATCC 15305 / DSM 20229 / NCIMB 8711 / NCTC 7292 / S-41) Type I restriction enzyme SsaAORF53P endonuclease subunit Proteins 0.000 description 2
• 208000006011 Stroke Diseases 0.000 description 2
• 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 2
• 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 2
• KERCOYANYUPLHJ-XGEHTFHBSA-N Thr-Pro-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O KERCOYANYUPLHJ-XGEHTFHBSA-N 0.000 description 2
• 108090000190 Thrombin Proteins 0.000 description 2
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
• 102000014384 Type C Phospholipases Human genes 0.000 description 2
• 108010079194 Type C Phospholipases Proteins 0.000 description 2
• ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
• 241000700605 Viruses Species 0.000 description 2
• 108010084455 Zeocin Proteins 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 230000003213 activating effect Effects 0.000 description 2
• 238000007792 addition Methods 0.000 description 2
• 238000001042 affinity chromatography Methods 0.000 description 2
• 239000008272 agar Substances 0.000 description 2
• 235000004279 alanine Nutrition 0.000 description 2
• 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 2
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
• 210000004727 amygdala Anatomy 0.000 description 2
• 230000000844 anti-bacterial effect Effects 0.000 description 2
• 230000003466 anti-cipated effect Effects 0.000 description 2
• 229940121375 antifungal agent Drugs 0.000 description 2
• 239000003429 antifungal agent Substances 0.000 description 2
• 235000010323 ascorbic acid Nutrition 0.000 description 2
• 229960005070 ascorbic acid Drugs 0.000 description 2
• 239000011668 ascorbic acid Substances 0.000 description 2
• 210000004227 basal ganglia Anatomy 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 230000000975 bioactive effect Effects 0.000 description 2
• 210000004958 brain cell Anatomy 0.000 description 2
• 210000000133 brain stem Anatomy 0.000 description 2
• AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• 239000001110 calcium chloride Substances 0.000 description 2
• 229910001628 calcium chloride Inorganic materials 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 210000001159 caudate nucleus Anatomy 0.000 description 2
• 239000013592 cell lysate Substances 0.000 description 2
• 210000000170 cell membrane Anatomy 0.000 description 2
• 238000005119 centrifugation Methods 0.000 description 2
• 206010008118 cerebral infarction Diseases 0.000 description 2
• 208000026106 cerebrovascular disease Diseases 0.000 description 2
• 235000013330 chicken meat Nutrition 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• 238000000975 co-precipitation Methods 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
• 230000009918 complex formation Effects 0.000 description 2
• 230000021615 conjugation Effects 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 210000000877 corpus callosum Anatomy 0.000 description 2
• 230000008878 coupling Effects 0.000 description 2
• 238000010168 coupling process Methods 0.000 description 2
• 238000005859 coupling reaction Methods 0.000 description 2
• 239000012228 culture supernatant Substances 0.000 description 2
• 235000018417 cysteine Nutrition 0.000 description 2
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
• 108010012052 cytochrome P-450 CYP2C subfamily Proteins 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 230000007547 defect Effects 0.000 description 2
• 239000003599 detergent Substances 0.000 description 2
• 150000001982 diacylglycerols Chemical class 0.000 description 2
• 230000004069 differentiation Effects 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 231100000676 disease causative agent Toxicity 0.000 description 2
• 230000004064 dysfunction Effects 0.000 description 2
• 238000001976 enzyme digestion Methods 0.000 description 2
• 206010015037 epilepsy Diseases 0.000 description 2
• 230000001747 exhibiting effect Effects 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 239000013613 expression plasmid Substances 0.000 description 2
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
• 210000001652 frontal lobe Anatomy 0.000 description 2
• 230000002538 fungal effect Effects 0.000 description 2
• 229960002963 ganciclovir Drugs 0.000 description 2
• IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 2
• 238000003205 genotyping method Methods 0.000 description 2
• 208000008605 glucosephosphate dehydrogenase deficiency Diseases 0.000 description 2
• 235000011187 glycerol Nutrition 0.000 description 2
• VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 2
• 230000012010 growth Effects 0.000 description 2
• 230000000971 hippocampal effect Effects 0.000 description 2
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
• 210000000987 immune system Anatomy 0.000 description 2
• 238000002649 immunization Methods 0.000 description 2
• 238000003018 immunoassay Methods 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• 230000000977 initiatory effect Effects 0.000 description 2
• 229960000367 inositol Drugs 0.000 description 2
• 230000002452 interceptive effect Effects 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 230000001057 ionotropic effect Effects 0.000 description 2
• 239000007951 isotonicity adjuster Substances 0.000 description 2
• 108010073472 leucyl-prolyl-proline Proteins 0.000 description 2
• 208000032839 leukemia Diseases 0.000 description 2
• 150000002632 lipids Chemical class 0.000 description 2
• 238000001638 lipofection Methods 0.000 description 2
• 239000007788 liquid Substances 0.000 description 2
• 210000004185 liver Anatomy 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 2
• 230000013011 mating Effects 0.000 description 2
• 210000001767 medulla oblongata Anatomy 0.000 description 2
• 239000002207 metabolite Substances 0.000 description 2
• 102000006239 metabotropic receptors Human genes 0.000 description 2
• 108020004083 metabotropic receptors Proteins 0.000 description 2
• 230000031864 metaphase Effects 0.000 description 2
• OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
• 244000005700 microbiome Species 0.000 description 2
• 230000005012 migration Effects 0.000 description 2
• 238000013508 migration Methods 0.000 description 2
• 230000003278 mimic effect Effects 0.000 description 2
• BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
• 201000006417 multiple sclerosis Diseases 0.000 description 2
• 210000000653 nervous system Anatomy 0.000 description 2
• 210000003061 neural cell Anatomy 0.000 description 2
• 230000004770 neurodegeneration Effects 0.000 description 2
• 208000029974 neurofibrosarcoma Diseases 0.000 description 2
• 238000001821 nucleic acid purification Methods 0.000 description 2
• 210000004940 nucleus Anatomy 0.000 description 2
• 235000015097 nutrients Nutrition 0.000 description 2
• 210000000869 occipital lobe Anatomy 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 210000001152 parietal lobe Anatomy 0.000 description 2
• 229940049954 penicillin Drugs 0.000 description 2
• 239000000816 peptidomimetic Substances 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• 239000000825 pharmaceutical preparation Substances 0.000 description 2
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
• CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 2
• 210000003635 pituitary gland Anatomy 0.000 description 2
• 238000007747 plating Methods 0.000 description 2
• 208000028173 post-traumatic stress disease Diseases 0.000 description 2
• 239000011591 potassium Substances 0.000 description 2
• 229910052700 potassium Inorganic materials 0.000 description 2
• 108020001213 potassium channel Proteins 0.000 description 2
• 238000001556 precipitation Methods 0.000 description 2
• 230000035935 pregnancy Effects 0.000 description 2
• 239000002987 primer (paints) Substances 0.000 description 2
• 230000002035 prolonged effect Effects 0.000 description 2
• 108010070643 prolylglutamic acid Proteins 0.000 description 2
• 230000000069 prophylactic effect Effects 0.000 description 2
• 230000005855 radiation Effects 0.000 description 2
• 238000000163 radioactive labelling Methods 0.000 description 2
• 239000012857 radioactive material Substances 0.000 description 2
• 230000004043 responsiveness Effects 0.000 description 2
• CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
• 229960002101 secretin Drugs 0.000 description 2
• OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
• 210000000278 spinal cord Anatomy 0.000 description 2
• 229960005322 streptomycin Drugs 0.000 description 2
• 238000012916 structural analysis Methods 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 230000004083 survival effect Effects 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 208000024891 symptom Diseases 0.000 description 2
• 238000007910 systemic administration Methods 0.000 description 2
• 210000003478 temporal lobe Anatomy 0.000 description 2
• 210000001103 thalamus Anatomy 0.000 description 2
• RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
• 229960003087 tioguanine Drugs 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• 230000009466 transformation Effects 0.000 description 2
• 230000005945 translocation Effects 0.000 description 2
• 238000011269 treatment regimen Methods 0.000 description 2
• 238000010396 two-hybrid screening Methods 0.000 description 2
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
• 210000004291 uterus Anatomy 0.000 description 2
• 239000003981 vehicle Substances 0.000 description 2
• 239000013603 viral vector Substances 0.000 description 2
• 238000001262 western blot Methods 0.000 description 2
• 229940075420 xanthine Drugs 0.000 description 2
• 210000005253 yeast cell Anatomy 0.000 description 2
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
• NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
• YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 description 1
• DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
• ZZKNRXZVGOYGJT-VKHMYHEASA-N (2s)-2-[(2-phosphonoacetyl)amino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)CP(O)(O)=O ZZKNRXZVGOYGJT-VKHMYHEASA-N 0.000 description 1
• ZGNLFUXWZJGETL-YUSKDDKASA-N (Z)-[(2S)-2-amino-2-carboxyethyl]-hydroxyimino-oxidoazanium Chemical compound N[C@@H](C\[N+]([O-])=N\O)C(O)=O ZGNLFUXWZJGETL-YUSKDDKASA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
• NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 1
• HLYBTPMYFWWNJN-UHFFFAOYSA-N 2-(2,4-dioxo-1h-pyrimidin-5-yl)-2-hydroxyacetic acid Chemical compound OC(=O)C(O)C1=CNC(=O)NC1=O HLYBTPMYFWWNJN-UHFFFAOYSA-N 0.000 description 1
• SGAKLDIYNFXTCK-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)methylamino]acetic acid Chemical compound OC(=O)CNCC1=CNC(=O)NC1=O SGAKLDIYNFXTCK-UHFFFAOYSA-N 0.000 description 1
• XMSMHKMPBNTBOD-UHFFFAOYSA-N 2-dimethylamino-6-hydroxypurine Chemical compound N1C(N(C)C)=NC(=O)C2=C1N=CN2 XMSMHKMPBNTBOD-UHFFFAOYSA-N 0.000 description 1
• SMADWRYCYBUIKH-UHFFFAOYSA-N 2-methyl-7h-purin-6-amine Chemical compound CC1=NC(N)=C2NC=NC2=N1 SMADWRYCYBUIKH-UHFFFAOYSA-N 0.000 description 1
• FUBFWTUFPGFHOJ-UHFFFAOYSA-N 2-nitrofuran Chemical class [O-][N+](=O)C1=CC=CO1 FUBFWTUFPGFHOJ-UHFFFAOYSA-N 0.000 description 1
• ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
• KOLPWZCZXAMXKS-UHFFFAOYSA-N 3-methylcytosine Chemical compound CN1C(N)=CC=NC1=O KOLPWZCZXAMXKS-UHFFFAOYSA-N 0.000 description 1
• GJAKJCICANKRFD-UHFFFAOYSA-N 4-acetyl-4-amino-1,3-dihydropyrimidin-2-one Chemical compound CC(=O)C1(N)NC(=O)NC=C1 GJAKJCICANKRFD-UHFFFAOYSA-N 0.000 description 1
• TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
• MQJSSLBGAQJNER-UHFFFAOYSA-N 5-(methylaminomethyl)-1h-pyrimidine-2,4-dione Chemical compound CNCC1=CNC(=O)NC1=O MQJSSLBGAQJNER-UHFFFAOYSA-N 0.000 description 1
• WPYRHVXCOQLYLY-UHFFFAOYSA-N 5-[(methoxyamino)methyl]-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CONCC1=CNC(=S)NC1=O WPYRHVXCOQLYLY-UHFFFAOYSA-N 0.000 description 1
• LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
• VKLFQTYNHLDMDP-PNHWDRBUSA-N 5-carboxymethylaminomethyl-2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C(CNCC(O)=O)=C1 VKLFQTYNHLDMDP-PNHWDRBUSA-N 0.000 description 1
• ZFTBZKVVGZNMJR-UHFFFAOYSA-N 5-chlorouracil Chemical compound ClC1=CNC(=O)NC1=O ZFTBZKVVGZNMJR-UHFFFAOYSA-N 0.000 description 1
• KSNXJLQDQOIRIP-UHFFFAOYSA-N 5-iodouracil Chemical compound IC1=CNC(=O)NC1=O KSNXJLQDQOIRIP-UHFFFAOYSA-N 0.000 description 1
• KELXHQACBIUYSE-UHFFFAOYSA-N 5-methoxy-1h-pyrimidine-2,4-dione Chemical compound COC1=CNC(=O)NC1=O KELXHQACBIUYSE-UHFFFAOYSA-N 0.000 description 1
• LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
• DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 1
• CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
• MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
• 208000030507 AIDS Diseases 0.000 description 1
• 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 description 1
• 102000012440 Acetylcholinesterase Human genes 0.000 description 1
• 108010022752 Acetylcholinesterase Proteins 0.000 description 1
• 208000032194 Acute haemorrhagic leukoencephalitis Diseases 0.000 description 1
• 229930024421 Adenine Natural products 0.000 description 1
• 201000011452 Adrenoleukodystrophy Diseases 0.000 description 1
• 206010067484 Adverse reaction Diseases 0.000 description 1
• 208000017194 Affective disease Diseases 0.000 description 1
• 206010001497 Agitation Diseases 0.000 description 1
• HXNNRBHASOSVPG-GUBZILKMSA-N Ala-Glu-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O HXNNRBHASOSVPG-GUBZILKMSA-N 0.000 description 1
• XRUJOVRWNMBAAA-NHCYSSNCSA-N Ala-Phe-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 XRUJOVRWNMBAAA-NHCYSSNCSA-N 0.000 description 1
• CYBJZLQSUJEMAS-LFSVMHDDSA-N Ala-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](C)N)O CYBJZLQSUJEMAS-LFSVMHDDSA-N 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• CZUHPNLXLWMYMG-UBHSHLNASA-N Arg-Phe-Ala Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CC1=CC=CC=C1 CZUHPNLXLWMYMG-UBHSHLNASA-N 0.000 description 1
• 108020005224 Arylamine N-acetyltransferase Proteins 0.000 description 1
• 102100038110 Arylamine N-acetyltransferase 2 Human genes 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 206010003591 Ataxia Diseases 0.000 description 1
• 206010003694 Atrophy Diseases 0.000 description 1
• 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
• 206010003805 Autism Diseases 0.000 description 1
• 208000020706 Autistic disease Diseases 0.000 description 1
• 108090001008 Avidin Proteins 0.000 description 1
• 208000000412 Avitaminosis Diseases 0.000 description 1
• 102100039705 Beta-2 adrenergic receptor Human genes 0.000 description 1
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
• 208000020925 Bipolar disease Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 208000004020 Brain Abscess Diseases 0.000 description 1
• 206010048962 Brain oedema Diseases 0.000 description 1
• 206010006143 Brain stem glioma Diseases 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• 208000032841 Bulimia Diseases 0.000 description 1
• 206010006550 Bulimia nervosa Diseases 0.000 description 1
• 101150019620 CAD gene Proteins 0.000 description 1
• 101150010738 CYP2D6 gene Proteins 0.000 description 1
• 102000055006 Calcitonin Human genes 0.000 description 1
• 108010001789 Calcitonin Receptors Proteins 0.000 description 1
• 240000001432 Calendula officinalis Species 0.000 description 1
• 235000005881 Calendula officinalis Nutrition 0.000 description 1
• 208000022526 Canavan disease Diseases 0.000 description 1
• UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• 108091005462 Cation channels Proteins 0.000 description 1
• 108091006146 Channels Proteins 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• 108020004394 Complementary RNA Proteins 0.000 description 1
• 208000027691 Conduct disease Diseases 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 229920000742 Cotton Polymers 0.000 description 1
• 108010051219 Cre recombinase Proteins 0.000 description 1
• 241000338702 Cupido minimus Species 0.000 description 1
• 101710095468 Cyclase Proteins 0.000 description 1
• 108700020473 Cyclic AMP Receptor Proteins 0.000 description 1
• 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
• 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
• GGRDJANMZPGMNS-CIUDSAMLSA-N Cys-Ser-Leu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O GGRDJANMZPGMNS-CIUDSAMLSA-N 0.000 description 1
• 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 1
• 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
• 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
• 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 1
• 241000701022 Cytomegalovirus Species 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 108010017826 DNA Polymerase I Proteins 0.000 description 1
• 102000004594 DNA Polymerase I Human genes 0.000 description 1
• 230000004544 DNA amplification Effects 0.000 description 1
• 238000001712 DNA sequencing Methods 0.000 description 1
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
• XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
• CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
• 206010012218 Delirium Diseases 0.000 description 1
• NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 1
• 206010012289 Dementia Diseases 0.000 description 1
• 206010012305 Demyelination Diseases 0.000 description 1
• 206010012335 Dependence Diseases 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• 208000012239 Developmental disease Diseases 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 241000168726 Dictyostelium discoideum Species 0.000 description 1
• 241000255601 Drosophila melanogaster Species 0.000 description 1
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
• 208000012661 Dyskinesia Diseases 0.000 description 1
• 208000014094 Dystonic disease Diseases 0.000 description 1
• 238000012286 ELISA Assay Methods 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 206010014612 Encephalitis viral Diseases 0.000 description 1
• 108010067770 Endopeptidase K Proteins 0.000 description 1
• 241000792859 Enema Species 0.000 description 1
• 108010013369 Enteropeptidase Proteins 0.000 description 1
• 102100029727 Enteropeptidase Human genes 0.000 description 1
• 206010014967 Ependymoma Diseases 0.000 description 1
• YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
• QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 1
• 108700024394 Exon Proteins 0.000 description 1
• 206010061846 Extradural abscess Diseases 0.000 description 1
• 108010046276 FLP recombinase Proteins 0.000 description 1
• 108010074860 Factor Xa Proteins 0.000 description 1
• 108010003471 Fetal Proteins Proteins 0.000 description 1
• 102000004641 Fetal Proteins Human genes 0.000 description 1
• BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
• 206010017065 Foster-Kennedy Syndrome Diseases 0.000 description 1
• 208000024412 Friedreich ataxia Diseases 0.000 description 1
• 201000011240 Frontotemporal dementia Diseases 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 102000027582 GPCRs class B Human genes 0.000 description 1
• 108091008883 GPCRs class B Proteins 0.000 description 1
• 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
• 108091006109 GTPases Proteins 0.000 description 1
• 102400001370 Galanin Human genes 0.000 description 1
• 101800002068 Galanin Proteins 0.000 description 1
• 108010001515 Galectin 4 Proteins 0.000 description 1
• 102100039556 Galectin-4 Human genes 0.000 description 1
• 206010018338 Glioma Diseases 0.000 description 1
• 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 102000018899 Glutamate Receptors Human genes 0.000 description 1
• 108010027915 Glutamate Receptors Proteins 0.000 description 1
• 108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
• IEFJWDNGDZAYNZ-BYPYZUCNSA-N Gly-Glu Chemical compound NCC(=O)N[C@H](C(O)=O)CCC(O)=O IEFJWDNGDZAYNZ-BYPYZUCNSA-N 0.000 description 1
• 108010051696 Growth Hormone Proteins 0.000 description 1
• 241000288105 Grus Species 0.000 description 1
• 206010018910 Haemolysis Diseases 0.000 description 1
• 206010018985 Haemorrhage intracranial Diseases 0.000 description 1
• 208000009889 Herpes Simplex Diseases 0.000 description 1
• 101000884399 Homo sapiens Arylamine N-acetyltransferase 2 Proteins 0.000 description 1
• 101100231743 Homo sapiens HPRT1 gene Proteins 0.000 description 1
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
• 102000003839 Human Proteins Human genes 0.000 description 1
• 108090000144 Human Proteins Proteins 0.000 description 1
• 241000701109 Human adenovirus 2 Species 0.000 description 1
• 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
• 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
• 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
• 208000023105 Huntington disease Diseases 0.000 description 1
• 241000243251 Hydra Species 0.000 description 1
• 206010020523 Hydromyelia Diseases 0.000 description 1
• 206010020772 Hypertension Diseases 0.000 description 1
• 206010058558 Hypoperfusion Diseases 0.000 description 1
• 208000001953 Hypotension Diseases 0.000 description 1
• 206010021143 Hypoxia Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 241001580033 Imma Species 0.000 description 1
• 208000001019 Inborn Errors Metabolism Diseases 0.000 description 1
• 208000026350 Inborn Genetic disease Diseases 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 229930010555 Inosine Natural products 0.000 description 1
• UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
• 208000008574 Intracranial Hemorrhages Diseases 0.000 description 1
• 201000008450 Intracranial aneurysm Diseases 0.000 description 1
• 108091092195 Intron Proteins 0.000 description 1
• HYVABZIGRDEKCD-UHFFFAOYSA-N Isopentenyladenine Natural products CC(C)=CCNC1=NC=NC2=C1N=CN2 HYVABZIGRDEKCD-UHFFFAOYSA-N 0.000 description 1
• 108010025815 Kanamycin Kinase Proteins 0.000 description 1
• 208000028226 Krabbe disease Diseases 0.000 description 1
• MLFKVJCWGUZWNV-UHFFFAOYSA-N L-alanosine Natural products OC(=O)C(N)CN(O)N=O MLFKVJCWGUZWNV-UHFFFAOYSA-N 0.000 description 1
• LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 208000004552 Lacunar Stroke Diseases 0.000 description 1
• DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
• 239000006137 Luria-Bertani broth Substances 0.000 description 1
• GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
• 208000000172 Medulloblastoma Diseases 0.000 description 1
• 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• 244000246386 Mentha pulegium Species 0.000 description 1
• 235000016257 Mentha pulegium Nutrition 0.000 description 1
• 235000004357 Mentha x piperita Nutrition 0.000 description 1
• 102000016193 Metabotropic glutamate receptors Human genes 0.000 description 1
• 108010010914 Metabotropic glutamate receptors Proteins 0.000 description 1
• 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 1
• 102000003792 Metallothionein Human genes 0.000 description 1
• 108090000157 Metallothionein Proteins 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 208000019695 Migraine disease Diseases 0.000 description 1
• 208000019022 Mood disease Diseases 0.000 description 1
• 208000026072 Motor neurone disease Diseases 0.000 description 1
• 101100018717 Mus musculus Il1rl1 gene Proteins 0.000 description 1
• 208000007101 Muscle Cramp Diseases 0.000 description 1
• 208000021642 Muscular disease Diseases 0.000 description 1
• 206010028570 Myelopathy Diseases 0.000 description 1
• 201000009623 Myopathy Diseases 0.000 description 1
• SGSSKEDGVONRGC-UHFFFAOYSA-N N(2)-methylguanine Chemical compound O=C1NC(NC)=NC2=C1N=CN2 SGSSKEDGVONRGC-UHFFFAOYSA-N 0.000 description 1
• NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
• 108010002311 N-glycylglutamic acid Proteins 0.000 description 1
• 241000244206 Nematoda Species 0.000 description 1
• 201000005118 Nephrogenic diabetes insipidus Diseases 0.000 description 1
• 206010052057 Neuroborreliosis Diseases 0.000 description 1
• 201000004404 Neurofibroma Diseases 0.000 description 1
• 102000008763 Neurofilament Proteins Human genes 0.000 description 1
• 108010088373 Neurofilament Proteins Proteins 0.000 description 1
• 208000032234 No therapeutic response Diseases 0.000 description 1
• 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
• 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
• 108700020796 Oncogene Proteins 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 101710160107 Outer membrane protein A Proteins 0.000 description 1
• 206010033128 Ovarian cancer Diseases 0.000 description 1
• 101150037263 PIP2 gene Proteins 0.000 description 1
• 208000027089 Parkinsonian disease Diseases 0.000 description 1
• 206010034010 Parkinsonism Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 102000057297 Pepsin A Human genes 0.000 description 1
• 108090000284 Pepsin A Proteins 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108010067902 Peptide Library Proteins 0.000 description 1
• 208000031839 Peripheral nerve sheath tumour malignant Diseases 0.000 description 1
• 206010048734 Phakomatosis Diseases 0.000 description 1
• UHRNIXJAGGLKHP-DLOVCJGASA-N Phe-Ala-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O UHRNIXJAGGLKHP-DLOVCJGASA-N 0.000 description 1
• NYQBYASWHVRESG-MIMYLULJSA-N Phe-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 NYQBYASWHVRESG-MIMYLULJSA-N 0.000 description 1
• 108010002724 Pheromone Receptors Proteins 0.000 description 1
• 206010034912 Phobia Diseases 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• 108010004729 Phycoerythrin Proteins 0.000 description 1
• 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
• 208000024571 Pick disease Diseases 0.000 description 1
• 201000007286 Pilocytic astrocytoma Diseases 0.000 description 1
• 208000007641 Pinealoma Diseases 0.000 description 1
• 208000000474 Poliomyelitis Diseases 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• 239000004793 Polystyrene Substances 0.000 description 1
• 102100037681 Protein FEV Human genes 0.000 description 1
• 101710198166 Protein FEV Proteins 0.000 description 1
• 239000012083 RIPA buffer Substances 0.000 description 1
• 108091034057 RNA (poly(A)) Proteins 0.000 description 1
• 108091030071 RNAI Proteins 0.000 description 1
• 206010037742 Rabies Diseases 0.000 description 1
• 241000711798 Rabies lyssavirus Species 0.000 description 1
• 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
• 108020005091 Replication Origin Proteins 0.000 description 1
• 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
• 206010038997 Retroviral infections Diseases 0.000 description 1
• 102100040756 Rhodopsin Human genes 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 101150006985 STE2 gene Proteins 0.000 description 1
• 101100262439 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) UBA2 gene Proteins 0.000 description 1
• 229920002684 Sepharose Polymers 0.000 description 1
• MOVJSUIKUNCVMG-ZLUOBGJFSA-N Ser-Cys-Ser Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)O)N)O MOVJSUIKUNCVMG-ZLUOBGJFSA-N 0.000 description 1
• XZKQVQKUZMAADP-IMJSIDKUSA-N Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(O)=O XZKQVQKUZMAADP-IMJSIDKUSA-N 0.000 description 1
• HHJFMHQYEAAOBM-ZLUOBGJFSA-N Ser-Ser-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O HHJFMHQYEAAOBM-ZLUOBGJFSA-N 0.000 description 1
• 208000036623 Severe mental retardation Diseases 0.000 description 1
• 208000009106 Shy-Drager Syndrome Diseases 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
• 108050001286 Somatostatin Receptor Proteins 0.000 description 1
• 102000011096 Somatostatin receptor Human genes 0.000 description 1
• 102100038803 Somatotropin Human genes 0.000 description 1
• 208000005392 Spasm Diseases 0.000 description 1
• 241000251131 Sphyrna Species 0.000 description 1
• 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 1
• 208000010112 Spinocerebellar Degenerations Diseases 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
• 201000000002 Subdural Empyema Diseases 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 206010042928 Syringomyelia Diseases 0.000 description 1
• 230000024932 T cell mediated immunity Effects 0.000 description 1
• 108091008874 T cell receptors Proteins 0.000 description 1
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
• 101710137500 T7 RNA polymerase Proteins 0.000 description 1
• 101150003725 TK gene Proteins 0.000 description 1
• 108010006785 Taq Polymerase Proteins 0.000 description 1
• 241000255588 Tephritidae Species 0.000 description 1
• 241000223892 Tetrahymena Species 0.000 description 1
• JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
• 102000006601 Thymidine Kinase Human genes 0.000 description 1
• 108020004440 Thymidine kinase Proteins 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 206010044565 Tremor Diseases 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• 208000026911 Tuberous sclerosis complex Diseases 0.000 description 1
• 241000397921 Turbellaria Species 0.000 description 1
• QIVPZSWBBHRNBA-JYJNAYRXSA-N Val-Pro-Phe Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(O)=O QIVPZSWBBHRNBA-JYJNAYRXSA-N 0.000 description 1
• HTONZBWRYUKUKC-RCWTZXSCSA-N Val-Thr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HTONZBWRYUKUKC-RCWTZXSCSA-N 0.000 description 1
• 208000009443 Vascular Malformations Diseases 0.000 description 1
• 108090000643 Vasopressin Receptors Proteins 0.000 description 1
• 240000006677 Vicia faba Species 0.000 description 1
• 235000010749 Vicia faba Nutrition 0.000 description 1
• 235000002098 Vicia faba var. major Nutrition 0.000 description 1
• 108020000999 Viral RNA Proteins 0.000 description 1
• 206010047627 Vitamin deficiencies Diseases 0.000 description 1
• 102000003734 Voltage-Gated Potassium Channels Human genes 0.000 description 1
• 108090000013 Voltage-Gated Potassium Channels Proteins 0.000 description 1
• 102100038344 Vomeronasal type-1 receptor 2 Human genes 0.000 description 1
• 239000005862 Whey Substances 0.000 description 1
• 102000007544 Whey Proteins Human genes 0.000 description 1
• 108010046377 Whey Proteins Proteins 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 1
• MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 description 1
• 230000007488 abnormal function Effects 0.000 description 1
• 239000003070 absorption delaying agent Substances 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 150000001242 acetic acid derivatives Chemical class 0.000 description 1
• 229940022698 acetylcholinesterase Drugs 0.000 description 1
• 208000011039 acquired metabolic disease Diseases 0.000 description 1
• 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
• 230000036982 action potential Effects 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 239000008186 active pharmaceutical agent Substances 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 1
• 101150013582 adaD gene Proteins 0.000 description 1
• 229960000643 adenine Drugs 0.000 description 1
• OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical group C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
• 210000004100 adrenal gland Anatomy 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 230000006838 adverse reaction Effects 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 238000001261 affinity purification Methods 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 229950005033 alanosine Drugs 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 229960003896 aminopterin Drugs 0.000 description 1
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
• 230000000202 analgesic effect Effects 0.000 description 1
• 229940035676 analgesics Drugs 0.000 description 1
• 238000000137 annealing Methods 0.000 description 1
• 208000022531 anorexia Diseases 0.000 description 1
• 230000003042 antagnostic effect Effects 0.000 description 1
• 239000000730 antalgic agent Substances 0.000 description 1
• 230000000078 anti-malarial effect Effects 0.000 description 1
• 230000000840 anti-viral effect Effects 0.000 description 1
• 230000005875 antibody response Effects 0.000 description 1
• 210000000628 antibody-producing cell Anatomy 0.000 description 1
• 239000003430 antimalarial agent Substances 0.000 description 1
• 229940033495 antimalarials Drugs 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• 229940041181 antineoplastic drug Drugs 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 230000036506 anxiety Effects 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• OIRDTQYFTABQOQ-UHFFFAOYSA-N ara-adenosine Natural products Nc1ncnc2n(cnc12)C1OC(CO)C(O)C1O OIRDTQYFTABQOQ-UHFFFAOYSA-N 0.000 description 1
• 210000001130 astrocyte Anatomy 0.000 description 1
• 230000037444 atrophy Effects 0.000 description 1
• 230000002238 attenuated effect Effects 0.000 description 1
• 238000000376 autoradiography Methods 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 230000003385 bacteriostatic effect Effects 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
• 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 102000005936 beta-Galactosidase Human genes 0.000 description 1
• 108010005774 beta-Galactosidase Proteins 0.000 description 1
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
• 239000003833 bile salt Substances 0.000 description 1
• 229940093761 bile salts Drugs 0.000 description 1
• 108091008324 binding proteins Proteins 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 229920000249 biocompatible polymer Polymers 0.000 description 1
• 230000000035 biogenic effect Effects 0.000 description 1
• 239000013060 biological fluid Substances 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 238000007413 biotinylation Methods 0.000 description 1
• 230000006287 biotinylation Effects 0.000 description 1
• 230000036770 blood supply Effects 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 208000006752 brain edema Diseases 0.000 description 1
• 208000029028 brain injury Diseases 0.000 description 1
• 239000007853 buffer solution Substances 0.000 description 1
• DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
• 235000014121 butter Nutrition 0.000 description 1
• 230000003491 cAMP production Effects 0.000 description 1
• 238000010804 cDNA synthesis Methods 0.000 description 1
• BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
• 229960004015 calcitonin Drugs 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229910002092 carbon dioxide Inorganic materials 0.000 description 1
• 229910002091 carbon monoxide Inorganic materials 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 238000000423 cell based assay Methods 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 230000012292 cell migration Effects 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 208000015114 central nervous system disease Diseases 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 230000035605 chemotaxis Effects 0.000 description 1
• 201000005353 childhood germ cell brain tumor Diseases 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 239000013611 chromosomal DNA Substances 0.000 description 1
• 230000008711 chromosomal rearrangement Effects 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 230000027288 circadian rhythm Effects 0.000 description 1
• 150000001860 citric acid derivatives Chemical class 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 229960004126 codeine Drugs 0.000 description 1
• 230000019771 cognition Effects 0.000 description 1
• 230000003920 cognitive function Effects 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
• 230000001332 colony forming effect Effects 0.000 description 1
• 238000013329 compounding Methods 0.000 description 1
• 238000012790 confirmation Methods 0.000 description 1
• 230000037011 constitutive activity Effects 0.000 description 1
• 238000011109 contamination Methods 0.000 description 1
• 230000008602 contraction Effects 0.000 description 1
• 239000013068 control sample Substances 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 235000019788 craving Nutrition 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 210000004748 cultured cell Anatomy 0.000 description 1
• ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
• 229960003067 cystine Drugs 0.000 description 1
• SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
• SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
• HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
• NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 206010061428 decreased appetite Diseases 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 239000003398 denaturant Substances 0.000 description 1
• 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 238000002405 diagnostic procedure Methods 0.000 description 1
• UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 229940000406 drug candidate Drugs 0.000 description 1
• 230000000857 drug effect Effects 0.000 description 1
• 230000036267 drug metabolism Effects 0.000 description 1
• 238000007877 drug screening Methods 0.000 description 1
• 239000003596 drug target Substances 0.000 description 1
• 208000010118 dystonia Diseases 0.000 description 1
• 239000012636 effector Substances 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 210000002308 embryonic cell Anatomy 0.000 description 1
• 239000007920 enema Substances 0.000 description 1
• 229940079360 enema for constipation Drugs 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 238000009585 enzyme analysis Methods 0.000 description 1
• 201000000165 epidural abscess Diseases 0.000 description 1
• 230000001667 episodic effect Effects 0.000 description 1
• 239000003797 essential amino acid Substances 0.000 description 1
• 235000020776 essential amino acid Nutrition 0.000 description 1
• 238000012869 ethanol precipitation Methods 0.000 description 1
• 239000005038 ethylene vinyl acetate Substances 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 239000012091 fetal bovine serum Substances 0.000 description 1
• 239000012894 fetal calf serum Substances 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 230000003619 fibrillary effect Effects 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
• 239000007850 fluorescent dye Substances 0.000 description 1
• 229960002949 fluorouracil Drugs 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 230000037406 food intake Effects 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 230000005714 functional activity Effects 0.000 description 1
• 238000010230 functional analysis Methods 0.000 description 1
• IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 230000004545 gene duplication Effects 0.000 description 1
• 208000016361 genetic disease Diseases 0.000 description 1
• 238000010353 genetic engineering Methods 0.000 description 1
• 238000012248 genetic selection Methods 0.000 description 1
• 210000004907 gland Anatomy 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 125000005456 glyceride group Chemical group 0.000 description 1
• 101150106093 gpt gene Proteins 0.000 description 1
• 239000000122 growth hormone Substances 0.000 description 1
• ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
• UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
• 230000008588 hemolysis Effects 0.000 description 1
• 230000002440 hepatic effect Effects 0.000 description 1
• 102000034345 heterotrimeric G proteins Human genes 0.000 description 1
• 108091006093 heterotrimeric G proteins Proteins 0.000 description 1
• 229960001340 histamine Drugs 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 235000001050 hortel pimenta Nutrition 0.000 description 1
• 230000028996 humoral immune response Effects 0.000 description 1
• 208000003906 hydrocephalus Diseases 0.000 description 1
• OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 229910052739 hydrogen Inorganic materials 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• 201000001421 hyperglycemia Diseases 0.000 description 1
• 230000001631 hypertensive effect Effects 0.000 description 1
• 201000009939 hypertensive encephalopathy Diseases 0.000 description 1
• 230000036543 hypotension Effects 0.000 description 1
• 210000003016 hypothalamus Anatomy 0.000 description 1
• 230000007954 hypoxia Effects 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 230000003100 immobilizing effect Effects 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 238000003119 immunoblot Methods 0.000 description 1
• 238000010166 immunofluorescence Methods 0.000 description 1
• 230000005847 immunogenicity Effects 0.000 description 1
• 230000016784 immunoglobulin production Effects 0.000 description 1
• 229940072221 immunoglobulins Drugs 0.000 description 1
• 230000003308 immunostimulating effect Effects 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 230000001976 improved effect Effects 0.000 description 1
• 238000005462 in vivo assay Methods 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 208000016245 inborn errors of metabolism Diseases 0.000 description 1
• 239000003701 inert diluent Substances 0.000 description 1
• 230000007574 infarction Effects 0.000 description 1
• 239000012678 infectious agent Substances 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 208000015978 inherited metabolic disease Diseases 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 229960003786 inosine Drugs 0.000 description 1
• 238000007689 inspection Methods 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 230000031146 intracellular signal transduction Effects 0.000 description 1
• 201000009941 intracranial hypertension Diseases 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 208000028867 ischemia Diseases 0.000 description 1
• QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
• BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
• 238000005304 joining Methods 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 230000013016 learning Effects 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 208000036546 leukodystrophy Diseases 0.000 description 1
• 210000003715 limbic system Anatomy 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 210000001165 lymph node Anatomy 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 208000024714 major depressive disease Diseases 0.000 description 1
• 230000036244 malformation Effects 0.000 description 1
• 210000005075 mammary gland Anatomy 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 230000028161 membrane depolarization Effects 0.000 description 1
• 230000015654 memory Effects 0.000 description 1
• 206010027191 meningioma Diseases 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
• IZAGSTRIDUNNOY-UHFFFAOYSA-N methyl 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetate Chemical compound COC(=O)COC1=CNC(=O)NC1=O IZAGSTRIDUNNOY-UHFFFAOYSA-N 0.000 description 1
• HPZMWTNATZPBIH-UHFFFAOYSA-N methyl adenine Natural products CN1C=NC2=NC=NC2=C1N HPZMWTNATZPBIH-UHFFFAOYSA-N 0.000 description 1
• STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
• 229940012189 methyl orange Drugs 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 229960001047 methyl salicylate Drugs 0.000 description 1
• 230000011987 methylation Effects 0.000 description 1
• 238000007069 methylation reaction Methods 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 210000000274 microglia Anatomy 0.000 description 1
• 206010027599 migraine Diseases 0.000 description 1
• 235000013336 milk Nutrition 0.000 description 1
• 239000008267 milk Substances 0.000 description 1
• 210000004080 milk Anatomy 0.000 description 1
• 230000000394 mitotic effect Effects 0.000 description 1
• 238000001823 molecular biology technique Methods 0.000 description 1
• 230000004001 molecular interaction Effects 0.000 description 1
• SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 description 1
• 229960005181 morphine Drugs 0.000 description 1
• 210000000472 morula Anatomy 0.000 description 1
• 210000002161 motor neuron Anatomy 0.000 description 1
• 208000005264 motor neuron disease Diseases 0.000 description 1
• 239000002324 mouth wash Substances 0.000 description 1
• 229940051866 mouthwash Drugs 0.000 description 1
• 208000029200 multiple sclerosis variant Diseases 0.000 description 1
• 238000002887 multiple sequence alignment Methods 0.000 description 1
• 239000007922 nasal spray Substances 0.000 description 1
• 239000006218 nasal suppository Substances 0.000 description 1
• 229930014626 natural product Natural products 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 230000024717 negative regulation of secretion Effects 0.000 description 1
• 210000000478 neocortex Anatomy 0.000 description 1
• 208000023833 nerve sheath neoplasm Diseases 0.000 description 1
• 201000010193 neural tube defect Diseases 0.000 description 1
• 208000007538 neurilemmoma Diseases 0.000 description 1
• 208000022145 neurocutaneous syndrome Diseases 0.000 description 1
• 230000000955 neuroendocrine Effects 0.000 description 1
• 208000002761 neurofibromatosis 2 Diseases 0.000 description 1
• 208000022032 neurofibromatosis type 2 Diseases 0.000 description 1
• 210000005044 neurofilament Anatomy 0.000 description 1
• 210000004498 neuroglial cell Anatomy 0.000 description 1
• 230000007996 neuronal plasticity Effects 0.000 description 1
• 208000014500 neuronal tumor Diseases 0.000 description 1
• 208000002040 neurosyphilis Diseases 0.000 description 1
• 239000002858 neurotransmitter agent Substances 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 239000000346 nonvolatile oil Substances 0.000 description 1
• 238000007899 nucleic acid hybridization Methods 0.000 description 1
• 239000002853 nucleic acid probe Substances 0.000 description 1
• 238000011330 nucleic acid test Methods 0.000 description 1
• 239000002777 nucleoside Substances 0.000 description 1
• 150000003833 nucleoside derivatives Chemical class 0.000 description 1
• 210000001010 olfactory tubercle Anatomy 0.000 description 1
• 210000004248 oligodendroglia Anatomy 0.000 description 1
• 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
• 208000031237 olivopontocerebellar atrophy Diseases 0.000 description 1
• 238000011275 oncology therapy Methods 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 239000007800 oxidant agent Substances 0.000 description 1
• 230000001590 oxidative effect Effects 0.000 description 1
• 208000012111 paraneoplastic syndrome Diseases 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 229940111202 pepsin Drugs 0.000 description 1
• 239000000813 peptide hormone Substances 0.000 description 1
• 238000010647 peptide synthesis reaction Methods 0.000 description 1
• 230000009984 peri-natal effect Effects 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 210000001428 peripheral nervous system Anatomy 0.000 description 1
• 208000033808 peripheral neuropathy Diseases 0.000 description 1
• RLZZZVKAURTHCP-UHFFFAOYSA-N phenanthrene-3,4-diol Chemical compound C1=CC=C2C3=C(O)C(O)=CC=C3C=CC2=C1 RLZZZVKAURTHCP-UHFFFAOYSA-N 0.000 description 1
• 229960003742 phenol Drugs 0.000 description 1
• 239000002427 pheromone receptor Substances 0.000 description 1
• 208000019899 phobic disease Diseases 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 230000001766 physiological effect Effects 0.000 description 1
• 230000006461 physiological response Effects 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 230000001817 pituitary effect Effects 0.000 description 1
• 230000003169 placental effect Effects 0.000 description 1
• 210000005059 placental tissue Anatomy 0.000 description 1
• 239000013600 plasmid vector Substances 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 230000010287 polarization Effects 0.000 description 1
• 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 229920002401 polyacrylamide Polymers 0.000 description 1
• 239000008389 polyethoxylated castor oil Substances 0.000 description 1
• 239000004633 polyglycolic acid Substances 0.000 description 1
• 239000004626 polylactic acid Substances 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 229920002223 polystyrene Polymers 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• 230000024715 positive regulation of secretion Effects 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 230000002028 premature Effects 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
• 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 1
• 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• 108010029020 prolylglycine Proteins 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
• 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
• 210000004129 prosencephalon Anatomy 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• 235000019833 protease Nutrition 0.000 description 1
• 229940076155 protein modulator Drugs 0.000 description 1
• 238000001742 protein purification Methods 0.000 description 1
• 238000001243 protein synthesis Methods 0.000 description 1
• 230000004844 protein turnover Effects 0.000 description 1
• 230000004850 protein–protein interaction Effects 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• 208000020016 psychiatric disease Diseases 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 239000000376 reactant Substances 0.000 description 1
• 239000011535 reaction buffer Substances 0.000 description 1
• 239000011541 reaction mixture Substances 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 230000006798 recombination Effects 0.000 description 1
• 238000005215 recombination Methods 0.000 description 1
• 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
• 230000004648 relaxation of smooth muscle Effects 0.000 description 1
• 238000009877 rendering Methods 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 230000001177 retroviral effect Effects 0.000 description 1
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
• 229940081974 saccharin Drugs 0.000 description 1
• 235000019204 saccharin Nutrition 0.000 description 1
• 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
• 210000003296 saliva Anatomy 0.000 description 1
• 239000012266 salt solution Substances 0.000 description 1
• 150000003839 salts Chemical class 0.000 description 1
• 201000000980 schizophrenia Diseases 0.000 description 1
• 206010039667 schwannoma Diseases 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 239000006152 selective media Substances 0.000 description 1
• 210000000582 semen Anatomy 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 230000001953 sensory effect Effects 0.000 description 1
• 231100000004 severe toxicity Toxicity 0.000 description 1
• 210000002027 skeletal muscle Anatomy 0.000 description 1
• 208000019116 sleep disease Diseases 0.000 description 1
• 230000008454 sleep-wake cycle Effects 0.000 description 1
• 208000020685 sleep-wake disease Diseases 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
• 229910001415 sodium ion Inorganic materials 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 125000006850 spacer group Chemical group 0.000 description 1
• 208000002320 spinal muscular atrophy Diseases 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 238000003153 stable transfection Methods 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000005846 sugar alcohols Polymers 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 229940124530 sulfonamide Drugs 0.000 description 1
• 150000003456 sulfonamides Chemical class 0.000 description 1
• 210000003863 superior colliculi Anatomy 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000002511 suppository base Substances 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 208000035581 susceptibility to neural tube defects Diseases 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 230000005062 synaptic transmission Effects 0.000 description 1
• 208000001608 teratocarcinoma Diseases 0.000 description 1
• 238000012956 testing procedure Methods 0.000 description 1
• 210000001550 testis Anatomy 0.000 description 1
• 238000011285 therapeutic regimen Methods 0.000 description 1
• 235000019157 thiamine Nutrition 0.000 description 1
• KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
• 229960003495 thiamine Drugs 0.000 description 1
• 239000011721 thiamine Substances 0.000 description 1
• DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
• 229940104230 thymidine Drugs 0.000 description 1
• 210000001541 thymus gland Anatomy 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 210000003437 trachea Anatomy 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 230000001131 transforming effect Effects 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• 201000008827 tuberculosis Diseases 0.000 description 1
• 208000009999 tuberous sclerosis Diseases 0.000 description 1
• 238000003160 two-hybrid assay Methods 0.000 description 1
• HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
• ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
• 241000701161 unidentified adenovirus Species 0.000 description 1
• 241001515965 unidentified phage Species 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 229940035893 uracil Drugs 0.000 description 1
• 210000003932 urinary bladder Anatomy 0.000 description 1
• 238000002255 vaccination Methods 0.000 description 1
• 238000001291 vacuum drying Methods 0.000 description 1
• 238000009777 vacuum freeze-drying Methods 0.000 description 1
• 201000002498 viral encephalitis Diseases 0.000 description 1
• 230000000007 visual effect Effects 0.000 description 1
• 238000011179 visual inspection Methods 0.000 description 1
• 208000002670 vitamin B12 deficiency Diseases 0.000 description 1
• 208000006542 von Hippel-Lindau disease Diseases 0.000 description 1
• 239000011534 wash buffer Substances 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 239000008215 water for injection Substances 0.000 description 1
• WCNMEQDMUYVWMJ-JPZHCBQBSA-N wybutoxosine Chemical compound C1=NC=2C(=O)N3C(CC([C@H](NC(=O)OC)C(=O)OC)OO)=C(C)N=C3N(C)C=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WCNMEQDMUYVWMJ-JPZHCBQBSA-N 0.000 description 1
• 238000001086 yeast two-hybrid system Methods 0.000 description 1